Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Innate lymphocytes in solid human tumors

ABSTRACT: Innate lymphocytes in solid human tumors

PROVIDER: PRJNA863562 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20708400.fastq.gz	Fastqsanger.gz
	SRR20708365.fastq.gz	Fastqsanger.gz
	SRR20708366.fastq.gz	Fastqsanger.gz
	SRR20708367.fastq.gz	Fastqsanger.gz
	SRR20708368.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Innate lymphocytes in solid human tumors

Project description:Profiling innate lymphocytes, NK cells, MAIT cells and gd T cells, in colorectal and endometrial cancer

2023-05-05 | GSE210040 | GEO

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [human]

Project description:Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [human]

| PRJNA699478 | ENA

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [human]

Project description:Phosphoinositide 3-kinase δ (PI3Kδ) plays key roles in lymphocytes and inhibitors targeting this PI3K have been approved for hematological malignancies. While preclinical data in hematological and solid tumor models have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumor immunity, the impact of PI3Kδi in human solid tumors remains unknown. Here, we assessed the effects of the PI3Kδi AMG319 in patients with early stage head and neck cancer in a neoadjuvant, double-blind and placebo-controlled randomised phase-II trial. We find that PI3Kδ inhibition decreases tumor-infiltrating TREG cells and causes heightened cytotoxic potential of tumor-infiltrating CD8+ and CD4+ T cells. Loss of intratumoral TREG cells and an increase in the frequency of activated TREG cells in the blood post-treatment are indicative of systemic effects on TREG cell tissue retention and maintenance. At the chosen AMG319 dosing, the occurrence of immune-related adverse events caused treatment discontinuation in 43% of drug-treated patients, further suggestive of systemic effects on TREG cells. Consistent with this notion, in a murine syngeneic tumor model, PI3Kδi caused a decrease in TREG cells in both tumor and non-malignant tissues and affected TREG subtype composition, maintenance and functionality.

2022-03-02 | GSE166148 | GEO

Atlas Human Lymphocytes

Project description:Atlas Human Lymphocytes

| PRJEB5468 | ENA

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors

Project description:Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors

| PRJNA699473 | ENA

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [mouse]

2022-03-02 | GSE166149 | GEO

HuR-dependent NK cell expansion is required for control of solid tumors and long-term virus infection

Project description:Natural Killer (NK) cells are innate lymphocytes capable of controlling tumors and virus infections through direct lysis and cytokine production. NK cells also expand and accumulate in affected tissues, but the role of NK cell expansion in tumor and viral control is not well understood. Here, we describe that post-transcriptional regulation by the RNA-binding protein HuR is essential for NK cell expansion, without overtly affecting NK cell effector functions. HuR-dependent NK cell expansion facilitated control of solid tumors, but it was dispensable for control of tumor metastases. In virus infection, HuR-dependent NK cell expansion contributed to long-term viral control in the absence of adaptive immunity without affecting acute infection. HuR-deficient NK cells displayed defects in expression of and splicing in cell cycle-associated genes, including decreased expression and alternative splicing of Ska2, a component of the spindle and kinetochore complex that is involved in chromosome separation during cell division. Furthermore, we identified an essential role for SKA2 in NK cell expansion. These results show that post-transcriptional regulation by HuR specifically affects NK cell expansion which is required for control of several solid tumors and long-term virus infection.

2023-08-31 | GSE217392 | GEO

IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T-cell engager immunotherapy in solid tumors

Project description:Bispecific T-cell engagers (TCEs) show promising clinical efficacy in blood tumors, but their application to solid tumors with immunosuppressive environments remains challenging. Here, we show that Fc-fused IL-7 (rhIL-7-hyFc) changes the intratumoral CD8 T cell landscape, allowing TCE-immunotherapy to function effectively in solid tumors. In order to explore the transcriptomic changes induced by rhIL-7-hyFc or a combination of rhIL-7-hyFc and TCE treatment at the clonal level, we performed scRNA/TCR-seq.

2024-04-16 | GSE237266 | GEO

Microengineered transplantation of human solid tumors for in vitro studies of CAR T immunotherapy

Project description:Despite its proven efficacy for hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy has met with limited success in treating solid tumors. While this represents a significant clinical challenge in cancer immunotherapy, preclinical efforts to assess and improve the efficacy and safety of CAR T therapy are hindered by our limited ability to model, probe, and modulate the complexity of cancer-immune interactions in solid tumors. Here, we present a microengineered platform for in vitro reproduction, real-time imaging, and in-depth analysis of malignant human solid tumors during CAR T therapy. Using a compartmentalized device with an externally accessible interface, this system makes it possible to engineer three-dimensional organotypic constructs composed of human tumor explants that can be vascularized and perfused with blood-borne immune cells in a controlled manner. We first present a microphysiological model of adenocarcinoma tumors in the human lung infused with CAR-T cells to demonstrate its capabilities to reproduce the three essential steps of targeting solid tumors, including CAR T cell recognition of tumor-associated antigens, infiltration, and survival and effector function in the tumor microenvironment. Using flow cytometry and single-cell RNA sequencing, we probe how the phenotype of CAR T cells changes during their recruitment and persistence. Furthermore, we use the sequencing data to discover a therapeutic target that can be pharmacologically inhibited in our model to significantly increase CAR T cell trafficking and their anti-tumor effects, for which we also present specific biomarkers identified by untargeted metabolomics analysis. This work provides a potentially powerful approach for mechanistic studies and preclinical screening of adoptive cell therapies for cancer and other complex diseases.

2025-06-25 | GSE240121 | GEO

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [mouse]

Project description:Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [mouse]

| PRJNA699479 | ENA